Insider Trading activities of Biogen Inc. insiders. , Part 3

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Biogen Inc. since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Biogen Inc. since year 2005. (See page 1 of this report.) Table 2 shows the detailed insider transactions of Biogen Inc. since 2005. The reporting company's ticker symbol is BIIB. The reporting company's CIK number is 875045.
The total value of stock buying since 2005 is $119,996,839.
The total value of stock sales since 2005 is $580,098,411.
The total value of stock option exercises since 2005 is $243,892,560.



Table 2. Detailed insider stock purchases, sales, and option exercises of Biogen Inc. insiders (BIIB) , Part 3
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2012-06-04 Pawlicki Raymond (SVP, Chief Information Officer) Sale 1,068 126.45 135,048
2012-06-04 Posner Brian S (Director) Sale 2,400 126.45 303,480
2012-06-04 Posner Brian S (Director) Option Ex 2,400 71.38 171,312
2012-06-04 Pangia Robert W (Director) Sale 5,000 130.00 650,000
2012-06-04 Pangia Robert W (Director) Option Ex 5,000 36.94 184,700
2012-06-04 Sherwin Stephen A (Director) Sale 2,500 126.45 316,125
2012-06-01 Scangos George A (Chief Executive Officer) Sale 1,183 128.63 152,169
2012-05-02 Alexander Susan H (EVP, General Counsel) Sale 20,000 135.00 2,700,000
2012-05-02 Alexander Susan H (EVP, General Counsel) Option Ex 20,000 44.73 894,599
2012-05-02 Schenk Lynn (Director) Sale 14,455 135.00 1,951,425
2012-05-02 Schenk Lynn (Director) Option Ex 5,975 53.43 319,244
2012-04-25 Alexander Susan H (EVP, General Counsel) Sale 16,764 130.00 2,179,320
2012-04-25 Alexander Susan H (EVP, General Counsel) Option Ex 16,764 44.73 749,853
2012-04-04 Alexander Susan H (EVP, General Counsel) Sale 3,236 130.00 420,680
2012-04-04 Alexander Susan H (EVP, General Counsel) Option Ex 3,236 44.73 144,746
2012-03-08 Pangia Robert W (Director) Sale 7,500 120.00 900,000
2012-03-08 Pangia Robert W (Director) Option Ex 7,500 35.64 267,300
2012-02-29 Gagnon Robert E. (Vice President, Finance) Sale 717 115.51 82,820
2012-02-28 Gagnon Robert E. (Vice President, Finance) Sale 835 115.03 96,050
2012-02-27 Alexander Susan H (EVP, General Counsel) Sale 4,255 115.43 491,154
2012-02-24 Gagnon Robert E. (Vice President, Finance) Sale 1,054 115.53 121,768
2012-02-24 Gagnon Robert E. (Vice President, Finance) Option Ex 1,054 49.65 52,331
2012-02-24 Alexander Susan H (EVP, General Counsel) Sale 2,145 115.53 247,811
2012-02-23 Gagnon Robert E. (Vice President, Finance) Option Ex 1,223 .00 0
2012-02-23 Cox John (EVP Pharmaceutical Oper & Tech) Option Ex 2,600 .00 0
2012-02-23 Clancy Paul J (Executive VP and CFO) Option Ex 4,281 .00 0
2012-02-23 Alexander Susan H (EVP, General Counsel) Option Ex 3,822 .00 0
2012-02-14 Gagnon Robert E. (Vice President, Finance) Sale 560 118.61 66,421
2012-02-14 Kingsley Stuart A (EVP, Global Comm. Operations) Sale 1,247 118.61 147,906
2012-02-13 Alexander Susan H (EVP, General Counsel) Sale 2,842 118.01 335,384
2012-02-10 Scangos George A (Chief Executive Officer) Option Ex 18,833 .00 0
2012-02-09 Gagnon Robert E. (Vice President, Finance) Option Ex 861 .00 0
2012-02-09 Cox John (EVP Pharmaceutical Oper & Tech) Option Ex 4,692 .00 0
2012-02-09 Clancy Paul J (Executive VP and CFO) Option Ex 4,692 .00 0
2012-02-09 Kingsley Stuart A (EVP, Global Comm. Operations) Option Ex 1,826 .00 0
2012-02-09 Alexander Susan H (EVP, General Counsel) Option Ex 3,911 .00 0
2012-02-06 Kingsley Stuart A (EVP, Global Comm. Operations) Sale 3,110 121.03 376,403
2012-02-01 Granata Francesco (EVP Global Commercial Operatio) Option Ex 5,198 .00 0
2012-02-01 Clancy Paul J (Executive VP and CFO) Sale 21,400 120.00 2,568,000
2012-02-01 Clancy Paul J (Executive VP and CFO) Option Ex 21,400 55.53 1,188,449
2012-02-01 Kingsley Stuart A (EVP, Global Comm. Operations) Option Ex 4,587 .00 0
2012-02-01 Holtzman Steven H (EVP Corp Devel and Strategy) Option Ex 5,159 .00 0
2012-02-01 Leaming Nancy (Director) Sale 5,700 120.00 684,000
2012-02-01 Leaming Nancy (Director) Option Ex 5,700 59.17 337,269
2012-02-01 Williams Douglas E (EVP Research & Development) Option Ex 5,159 .00 0
2012-01-20 Leaming Nancy (Director) Sale 3,000 118.00 354,000
2012-01-20 Leaming Nancy (Director) Option Ex 3,000 55.97 167,910
2012-01-06 Rowinsky Eric K (Director) Sale 12,992 116.00 1,507,072
2012-01-06 Rowinsky Eric K (Director) Option Ex 12,992 59.82 777,181
2012-01-06 Leaming Nancy (Director) Sale 3,000 116.00 348,000
2012-01-06 Leaming Nancy (Director) Option Ex 3,000 55.97 167,910
2012-01-03 Clancy Paul J (Executive VP and CFO) Sale 20,244 112.46 2,276,559
2012-01-03 Leaming Nancy (Director) Sale 4,000 114.00 456,000
2012-01-03 Leaming Nancy (Director) Option Ex 4,000 55.97 223,880
2011-12-19 Sherwin Stephen A (Director) Sale 2,500 110.88 277,200
2011-12-06 Gagnon Robert E. (Chief Acct Officer VP & Contr) Sale 795 112.31 89,286
2011-11-09 Gagnon Robert E. (Chief Acct Officer VP & Contr) Sale 796 112.04 89,183
2011-11-01 Cox John (EVP Pharmaceutical Oper & Tech) Sale 2,175 114.37 248,754
2011-11-01 Cox John (EVP Pharmaceutical Oper & Tech) Option Ex 2,175 72.87 158,492
2011-10-05 Gagnon Robert E. (Chief Acct Officer VP & Contr) Sale 252 97.66 24,610
2011-10-03 Gagnon Robert E. (Chief Acct Officer VP & Contr) Sale 778 92.55 72,003
2011-10-03 Gagnon Robert E. (Chief Acct Officer VP & Contr) Option Ex 778 49.59 38,581
2011-09-27 Young William (Director) Sale 33,250 96.14 3,196,655
2011-09-27 Young William (Director) Option Ex 33,250 51.87 1,724,744
2011-09-16 Leaming Nancy (Director) Sale 3,085 100.00 308,500
2011-09-01 Young William (Director) Sale 35,000 95.00 3,325,000
2011-09-01 Young William (Director) Option Ex 35,000 45.86 1,604,995
2011-08-29 Posner Brian S (Director) Sale 15,000 92.53 1,387,890
2011-08-29 Posner Brian S (Director) Option Ex 15,000 71.38 1,070,700
2011-08-29 Young William (Director) Sale 10,000 92.58 925,780
2011-08-29 Young William (Director) Option Ex 10,000 68.15 681,500
2011-07-20 Scangos George A (Chief Executive Officer) Sale 12,347 106.42 1,313,992
2011-07-15 Scangos George A (Chief Executive Officer) Option Ex 21,341 .00 0
2011-07-01 Granata Francesco (EVP Global Commercial Operatio) Sale 2,901 107.52 311,918
2011-06-14 Leaming Nancy (Director) Sale 2,300 92.62 213,021
2011-05-26 Leaming Nancy (Director) Sale 33,175 93.24 3,093,237
2011-05-26 Leaming Nancy (Director) Option Ex 33,175 55.12 1,828,705
2011-05-26 Pangia Robert W (Director) Sale 15,000 93.27 1,399,035
2011-05-26 Pangia Robert W (Director) Option Ex 15,000 51.24 768,675
2011-05-25 Posner Brian S (Director) Sale 25,975 94.09 2,443,909
2011-05-25 Posner Brian S (Director) Option Ex 25,975 62.41 1,620,969
2011-05-06 Gagnon Robert E. (Chief Acct Officer VP & Contr) Sale 967 96.13 92,959
2011-05-04 Gagnon Robert E. (Chief Acct Officer VP & Contr) Sale 215 96.03 20,645
2011-05-02 Alexander Susan H (EVP, General Counsel) Sale 20,993 97.24 2,041,443
2011-04-28 Clancy Paul J (Executive VP and CFO) Sale 19,716 99.11 1,954,033
2011-04-28 Clancy Paul J (Executive VP and CFO) Option Ex 14,766 43.24 638,481
2011-04-21 Cox John (EVP Pharmaceutical Oper & Tech) Sale 4,350 100.00 435,000
2011-04-21 Cox John (EVP Pharmaceutical Oper & Tech) Option Ex 4,350 72.87 316,984
2011-04-20 Schenk Lynn (Director) Sale 37,275 85.40 3,183,434
2011-04-20 Schenk Lynn (Director) Option Ex 37,275 58.56 2,182,973
2011-04-13 Cox John (EVP Pharmaceutical Oper & Tech) Sale 36,234 80.00 2,898,720
2011-04-13 Cox John (EVP Pharmaceutical Oper & Tech) Option Ex 36,234 56.77 2,057,112
2011-04-11 Cox John (EVP Pharmaceutical Oper & Tech) Sale 6,900 78.00 538,200
2011-04-11 Cox John (EVP Pharmaceutical Oper & Tech) Option Ex 6,900 47.92 330,648
2011-03-31 Cox John (EVP Pharmaceutical Oper & Tech) Sale 2,840 73.00 207,320
2011-03-31 Cox John (EVP Pharmaceutical Oper & Tech) Option Ex 2,840 43.50 123,540
2011-03-05 Clancy Paul J (Executive VP and CFO) Option Ex 28,750 58.99 1,695,962
2011-03-02 Gagnon Robert E. (Chief Acct Officer VP & Contr) Sale 1,402 69.87 97,963
2011-03-02 Cox John (EVP Pharmaceutical Oper & Tech) Sale 4,041 70.21 283,722
2011-03-02 Schneier Craig Eric (EVP, HR, Public Affairs & Comm) Sale 7,511 70.21 527,332
2011-03-01 Schneier Craig Eric (EVP, HR, Public Affairs & Comm) Sale 6,250 68.62 428,875
2011-03-01 Schneier Craig Eric (EVP, HR, Public Affairs & Comm) Option Ex 6,250 49.65 310,312
2011-02-25 Schneier Craig Eric (EVP, HR, Public Affairs & Comm) Sale 9,725 68.20 663,245
2011-02-25 Schneier Craig Eric (EVP, HR, Public Affairs & Comm) Option Ex 9,725 49.31 479,539
2011-02-24 Gagnon Robert E. (Chief Acct Officer VP & Contr) Sale 1,054 66.99 70,606
2011-02-24 Gagnon Robert E. (Chief Acct Officer VP & Contr) Option Ex 1,054 49.65 52,331
2011-02-23 Gagnon Robert E. (Chief Acct Officer VP & Contr) Option Ex 1,006 .00 0
2011-02-23 Cox John (EVP Pharmaceutical Oper & Tech) Option Ex 2,138 .00 0
2011-02-23 Clancy Paul J (Executive VP and CFO) Option Ex 3,521 .00 0
2011-02-23 Alexander Susan H (EVP, General Counsel) Option Ex 3,144 .00 0
2011-02-23 Schneier Craig Eric (EVP, HR, Public Affairs & Comm) Option Ex 5,030 .00 0
2011-02-17 Gagnon Robert E. (Chief Acct Officer VP & Contr) Sale 732 67.10 49,115
2011-02-17 Cox John (EVP Pharmaceutical Oper & Tech) Sale 1,843 67.08 123,619
2011-02-17 Schneier Craig Eric (EVP, HR, Public Affairs & Comm) Sale 3,194 67.08 214,240
2011-02-01 Granata Francesco (EVP Global Commercial Operatio) Option Ex 4,286 .00 0
2011-01-20 Schneier Craig Eric (EVP, HR, Public Affairs & Comm) Sale 6,250 68.62 428,875
2011-01-20 Schneier Craig Eric (EVP, HR, Public Affairs & Comm) Option Ex 6,250 49.65 310,312
2011-01-04 Gagnon Robert E. (Chief Acct Officer VP & Contr) Sale 5,103 66.57 339,696
2011-01-04 Gagnon Robert E. (Chief Acct Officer VP & Contr) Option Ex 4,307 46.62 200,805
2010-12-31 Young William (Director) Option Ex 15,000 59.25 888,750
2010-12-30 Schenk Lynn (Director) Sale 15,000 66.80 1,001,985
2010-12-30 Schenk Lynn (Director) Option Ex 15,000 59.25 888,750
2010-12-17 Schneier Craig Eric (EVP, HR, Public Affairs & Comm) Sale 19,450 68.20 1,326,490
2010-12-17 Schneier Craig Eric (EVP, HR, Public Affairs & Comm) Option Ex 19,450 49.31 959,079
2010-12-07 Schneier Craig Eric (EVP, HR, Public Affairs & Comm) Sale 28,093 67.20 1,887,849
2010-12-07 Schneier Craig Eric (EVP, HR, Public Affairs & Comm) Option Ex 28,093 44.24 1,242,834
2010-12-06 Gagnon Robert E. (Chief Acct Officer VP & Contr) Sale 796 66.53 52,957
2010-12-03 Schneier Craig Eric (EVP, HR, Public Affairs & Comm) Sale 1,907 67.20 128,150
2010-12-03 Schneier Craig Eric (EVP, HR, Public Affairs & Comm) Option Ex 1,907 44.24 84,365
2010-11-09 Cox John (EVP Pharmaceutical Oper & Tech) Sale 773 62.87 48,596
2010-11-02 Cox John (EVP Pharmaceutical Oper & Tech) Sale 765 63.04 48,227
2010-10-28 Cox John (EVP Pharmaceutical Oper & Tech) Sale 6,900 63.00 434,700
2010-10-28 Cox John (EVP Pharmaceutical Oper & Tech) Option Ex 6,900 33.97 234,393
2010-10-28 Pangia Robert W (Director) Sale 15,000 64.00 960,000
2010-10-28 Pangia Robert W (Director) Option Ex 15,000 59.25 888,750
2010-08-13 Dorsa Caroline (Director) Buy 177 56.41 9,984
2010-08-02 Maclean Michael F (SVP, Chief Accounting Officer) Sale 9,542 56.86 542,548
2010-07-30 Dorsa Caroline (Director) Buy 183 54.57 9,986
2010-07-16 Dorsa Caroline (Director) Buy 185 53.71 9,936
2010-06-30 Dorsa Caroline (Director) Buy 205 48.63 9,969
2010-06-18 Dorsa Caroline (Director) Buy 203 49.15 9,976
2010-06-08 Leaming Nancy (Director) Sale 900 47.62 42,858
2010-06-08 Ross Bruce (Director) Sale 2,000 47.62 95,244
2010-05-28 Dorsa Caroline (Director) Buy 208 48.01 9,985
2010-05-14 Dorsa Caroline (Director) Buy 195 50.87 9,919
2010-04-30 Dorsa Caroline (Director) Buy 187 53.38 9,981
2010-04-23 Hamm Robert A (Chief Operating Officer) Sale 5,668 52.19 295,795
2010-03-22 Mullen James C (CEO & President) Sale 106,279 59.95 6,371,744
2010-03-22 Mullen James C (CEO & President) Option Ex 106,279 49.03 5,210,859
2010-03-19 Maclean Michael F (SVP, Chief Accounting Officer) Sale 4,085 60.00 245,100

Insider trading activities including stock purchases, stock sales, and option exercises of BIIB listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Biogen Inc. (symbol BIIB, CIK number 875045) see the Securities and Exchange Commission (SEC) website.